CD40 and neoplasm: Of note, agonistic antibodies are reported in several trials to have significant systemic side effects, including cytokine release syndrome and hepatotoxicity (174); the next generation of CD40 agonistic antibodies will need to bypass systemic toxicity, with some methods already being explored including local administration or engineered tumor-specific antibodies (177).